Published in Clin Cancer Res on April 12, 2011
Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer (2013) 1.56
Beyond the zebrafish: diverse fish species for modeling human disease. Dis Model Mech (2013) 1.19
Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med (2013) 1.11
Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer (2013) 1.00
TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One (2012) 0.99
A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med (2014) 0.91
Evaluating biomarkers in melanoma. Front Oncol (2015) 0.83
Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis. J Cell Physiol (2014) 0.83
Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Mol Cancer (2016) 0.80
Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett (2016) 0.79
Organ Specific Tumor Markers: What's New? Indian J Clin Biochem (2011) 0.77
Plasma osteopontin concentrations in patients with cutaneous melanoma. Oncol Rep (2013) 0.77
Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment. Mol Clin Oncol (2012) 0.76
Whole Body Melanoma Transcriptome Response in Medaka. PLoS One (2015) 0.75
Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients. J Neurooncol (2016) 0.75
Serum markers in early-stage and locally advanced melanoma. Tumour Biol (2015) 0.75
Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy. J Immunol Res (2015) 0.75
TIMP-1 and CD82, a promising combined evaluation marker for PDAC. Oncotarget (2016) 0.75
CEACAM1: Expression and Role in Melanocyte Transformation. Dis Markers (2016) 0.75
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis. J Neurooncol (2016) 0.75
Bioinformatic Analysis of Gene Expression for Melanoma Treatment. J Invest Dermatol (2016) 0.75
CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
UK guidelines for the management of cutaneous melanoma. Br J Plast Surg (2002) 3.51
Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol (2008) 1.76
Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol (2008) 1.68
Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol (2008) 1.45
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer (1999) 1.22
Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol (2008) 1.22
Osteopontin as a molecular prognostic marker for melanoma. Cancer (2008) 1.20
Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol (2008) 1.19
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol (2004) 1.08
Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer (2009) 1.07
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
Treatment options for limited or symptomatic metastatic melanoma. Cancer Control (2008) 1.03
Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur J Nucl Med (2000) 1.03
Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer (2009) 1.02
Serum markers to detect metastatic uveal melanoma. Anticancer Res (2007) 1.00
Imaging in cutaneous melanoma. Nucl Med Commun (2008) 0.95
Kinetics analysis of binding between melanoma cells and neutrophils. Mol Cell Biomech (2006) 0.95
Follow-up schedules after treatment for malignant melanoma. Br J Surg (2008) 0.92
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.90
Can surgeons improve survival in stage IV melanoma? J Surg Oncol (2008) 0.89
Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma. Arch Dermatol Res (2005) 0.89
Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.87
Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1. Oncology (2010) 0.87
Serum markers of cutaneous melanoma. Front Biosci (Elite Ed) (2010) 0.86
Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol (2008) 0.86
Therapeutic vaccines for melanoma: current status. BioDrugs (2005) 0.85
Macrophage inhibitory cytokine-1: a new player in melanoma development. J Invest Dermatol (2009) 0.83
Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol (2007) 0.80
Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res (1999) 0.79
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science (2003) 12.07
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell (2007) 4.93
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
An initial blueprint for myogenic differentiation. Genes Dev (2005) 4.22
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
A common set of gene regulatory networks links metabolism and growth inhibition. Mol Cell (2004) 3.37
PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell (2012) 3.28
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Survival ensembles. Biostatistics (2005) 2.88
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc Natl Acad Sci U S A (2011) 2.48
MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res (2008) 2.28
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) (2013) 2.05
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (2011) 1.99
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol (2006) 1.85
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
A role for mammalian Sin3 in permanent gene silencing. Mol Cell (2008) 1.59
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 1.57
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res (2008) 1.50
Picking ChIP-seq peak detectors for analyzing chromatin modification experiments. Nucleic Acids Res (2012) 1.49
Inter- and intra-combinatorial regulation by transcription factors and microRNAs. BMC Genomics (2007) 1.45
Cadaveric allograft for wound closure after resection of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a report of 32 resections and repairs in 2 patients. Ann Plast Surg (2009) 1.44
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst (2012) 1.42
Benefits and Risks of Prophylaxis for Deep Venous Thrombosis and Pulmonary Embolus in Plastic Surgery: A Systematic Review and Meta-Analysis of Controlled Trials and Consensus Conference. Plast Reconstr Surg (2016) 1.41
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 1.40
A proposal for the timing of management of patients with melanoma presenting during pregnancy. J Surg Oncol (2012) 1.40
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Functional Neck Dissection: The Operative Technique Series. Plast Reconstr Surg (2016) 1.39
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Identification and correction of spurious spatial correlations in microarray data. Biotechniques (2003) 1.38
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol (2012) 1.38
Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev (2006) 1.36
Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 1.33
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res (2003) 1.31
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30
Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics (2006) 1.27
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res (2011) 1.27
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res (2003) 1.24
TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Res (2013) 1.23
Close proximity to Igh is a contributing factor to AID-mediated translocations. Mol Cell (2012) 1.23
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
Gene expression in mature neutrophils: early responses to inflammatory stimuli. J Leukoc Biol (2003) 1.23
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res (2005) 1.22
Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. Blood (2002) 1.22
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res (2005) 1.20
Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am (2012) 1.19
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res (2004) 1.18
The mammalian Sin3 proteins are required for muscle development and sarcomere specification. Mol Cell Biol (2010) 1.17
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol (2004) 1.16
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol (2004) 1.14
Carbohydrates act as sorting determinants in ER-associated degradation of tyrosinase. J Cell Sci (2004) 1.14
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res (2005) 1.13
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res (2003) 1.13